Aclaris partners with Biosion for anti-TSLP programs and seeks $80M funding, Keymed Biosciences signs $626M potential deal with Ouro Medicines, ReCode receives CF Foundation funding, Quell gets $10M ...
Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback